Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 6,400 shares, an increase of 48.8% from the March 15th total of 4,300 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,900 shares, the short-interest ratio is presently 0.9 days.

Adlai Nortye Price Performance

Adlai Nortye stock opened at $1.71 on Friday. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.20. Adlai Nortye has a 52-week low of $1.69 and a 52-week high of $15.55.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.